R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Al-Sarayfi, Diana; Meeuwes, Frederik O.; Durmaz, Müjde; Issa, Djamila E.; Brouwer, Rolf E.; Beeker, Aart; van Rhenen, Anna; Mutsaers, Pim G.N.J.; Böhmer, Lara H.; van der Poel, Marjolein W.M.; te Boome, Liane; van Meerten, Tom; Chamuleau, Martine E.D.; Zijlstra, Josée M.; Brink, Mirian; Nijland, Marcel

doi:https://doi.org/10.1038/s41408-022-00723-4

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

DSpace/Manakin Repository

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Al-Sarayfi, Diana; Meeuwes, Frederik O.; Durmaz, Müjde; Issa, Djamila E.; Brouwer, Rolf E.; Beeker, Aart; van Rhenen, Anna; Mutsaers, Pim G.N.J.; Böhmer, Lara H.; van der Poel, Marjolein W.M.; te Boome, Liane; van Meerten, Tom; Chamuleau, Martine E.D.; Zijlstra, Josée M.; Brink, Mirian; Nijland, Marcel

(2022) Blood cancer journal, volume 12, issue 9

(Letter)

Download/Full Text

Open Access version via Utrecht University Repository

Publisher version

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Anthracyclines/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Cyclophosphamide/therapeutic use, Humans, Lymphoma, Large B-Cell, Diffuse/pathology, Prednisone/therapeutic use, Treatment Outcome, Vincristine/therapeutic use, Hematology, Oncology, Letter

DOI: https://doi.org/10.1038/s41408-022-00723-4

ISSN: 2044-5385

Publisher: Nature Publishing Group

(Peer reviewed)